Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association...

Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association Meeting

HASBROUCK HEIGHTS, N.J.--(Business Wire)--
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced
that new clinical trial data concerning the safety and efficacy of the
Company's NX-1207 for benign prostatic hyperplasia (BPH) will be
presented at the South Central Section of the American Urological
Association Meeting in San Diego in September. The paper is authored
by leading clinical research investigators participating in the U.S.
clinical trials of NX-1207.

NX-1207 is Nymox's patented drug candidate for the treatment of
BPH, a common affliction of men related to enlarged prostate. Blinded
clinical trials to date have shown that men treated with NX-1207
reported statistically significant improvement in BPH symptoms 3
months after a single NX-1207 treatment with no reported serious
drug-related side effects, including no (0%) significant sexual side
effects. In two multi-center Phase 2 U.S. prospective randomized
blinded clinical trials, the aggregated mean improvement in the
Primary Endpoint of BPH Symptom Score for 2.5 mg NX-1207 was 10.3
points or a 44% improvement in Symptom Score.

Data from the NX02-0016 study (announced by the Company on
February 6 and March 11, 2008) showed that NX-1207 markedly reduced
the incidence of nighttime urination (nocturia), a particularly
bothersome symptom associated with BPH. After 90 days, subjects
treated with a therapeutic dose of NX-1207 had a mean reduction in
nocturia symptom score of 41% versus 4% for subjects treated with
finasteride, an approved BPH treatment. This improvement was
statistically significant (p<.001). Having to repeatedly get up in the
night to urinate is a common symptom of BPH that can cause chronic
sleep loss and, in turn, lead to fatigue, memory deficits, mood
changes including depression, and increased risk of long term medical
problems.

Results of 5 follow-up studies of available subjects from NX-1207
clinical trials have provided evidence of durable benefits from
NX-1207 treatment for up to 3 1/2 years from the date of treatment.

BPH treatment represents a growing market with more than 100
million men worldwide being estimated to suffer from BPH symptoms. The
disorder is a common affliction of older men, affecting approximately
half of men over age 50 and close to 90% of men by age 80, and is
associated with growth in prostate size as men age. BPH causes
difficulties with urination associated with aging, such as urination
at night, urge to void frequently, hesitancy, weak stream, and other
problems, and can cause acute urinary retention requiring immediate
medical attention.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation Reform
Act of 1995 that involve a number of risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
the actual results and future events could differ materially from
management's current expectations. The conduct of clinical trials and
the development of drug products involve substantial risks and
uncertainties and actual results may differ materially from
expectations. Promising early results do not ensure that later stage
or larger scale clinical trials will be successful or will proceed as
expected. Such factors are detailed from time to time in Nymox's
filings with the United States Securities and Exchange Commission and
other regulatory authorities.

Nymox Pharmaceutical Corporation
Roy Wolvin, 800-93NYMOX
www.nymox.com

Copyright Business Wire 2008